Member Info for Luckenbach

Not everybody having holidays in Finland. With the following agreement today Orion signs 290m$ upfront. The Mcap of Orion rose today sofar by rough 9% meaning more than half a billion dollars.

https://www.orion.fi/en/Orion-group/media/stock-exchange-releases/2022/orion-and-msd-announce-global-collaboration-for-the-development-and-commercialisation-of-odm-208-an-investigational-steroid-synthesis-inhibitor-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer/?epieditmode=true

Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer
Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer
ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
13 JULY 2022 at 9.00 EEST
        
Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer
* Orion to receive an upfront payment of USD 290 million
* Agreement strengthens and complements MSD’s oncology pipeline
Orion Corporation (“Orion”) and MSD (tradename of Merck & Co., Inc. Rahway NJ USA) today announced a global development and commercialisation agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Sax, you are on fire. I support your feelings! Something great going on here.

So the website blocker must have been in place already before the LLS placing and maybe now for coming events too for sure because US is so much on the lips. Of course it’s very limited what and how @Paavo can comment on bb but welcome here too.

Could it be they are in negotiations to sell the company to US BP and the information on the website is not to be regarded as sales material. Could be plans for US listing too and the material differs from the red-herring?

With forty-seven kind of a valuation someone could start counting in billion(s). Some reason to believe one has to have when investing millions.

Hi Westernglory, well done. I am satisfied with my position and not investing more in here. Yes strong believe in Markku and Faron. Hopefully some day we get really good news. The later the bigger the stake we’ve been told. Optimizing or maximizing the benefit for all of us. No doubt they do their best and as soon as possible for the patients.

Hardly any of the top 100 owners have changed their position here. Some changes in positions among nominee registered. No excited new investors. For big funds a reasonable available amount of shares would still be too small sum of money?

Who ever really believes in this share takes it not as a timing business anymore IMO. Maybe some are expecting recovery happens sooner elsewhere in the market? Surely a change in a general market sentiment would help us but effects would be seen elsewhere first. With Faron it happens when it happens. I am afraid a general market boost is not in sight. Sitting and waiting with Faron is more relaxing and promising than having that sum in a bank account when possible.

Would be nice to know how many small investors have sold their shares and in what proportion compared to other’s trading activities? No matter for what reason even though we have had constant positive news.

Yes Cov, the exercise price is what you mentioned according to the 2019 option plan. It’s all together 497 000 share options representing 0.9 % of the share capital. The options can be vested between March 2023 and March 2027 meaning 25% each year. No problem.

Now we all could buy more shares cheaper.

Options are not an easy tool because there are always discrepancies who gets them based on prevailing position and performance and who don’t. For us shareholders the point is does it promote the success of the company and does it represent good governance and is it in balance with shareholder’s risk. So far no dividend and no benefit in SP. Employees do get their salaries.and they can deserve options if the founders do.. Anyway capital and investors are quite an important factor here too and this all should be in balance. It’s more a severe situation in loan and capital markets and it entities shareholders question how extra benefits are shared.

Is it now more scarce on capital or talent at Faron? I don’t know.

All the best for all of us.

Yes Felix, I hope so too!

As mentioned earlier great news concerning Bex results and we all are wondering why the SP is merely sinking than taking any benefit from the news. That’s not what we have been expecting and we try to understand the challenging market situation.

Have to correct that granting options does not stress the balance and does not endanger the share capital. It is a shareholder’s way to reward board members, management, personnel and advisory boar by diluting shareholders proportion of the ownership. Nothing wrong here and options are a useful tool for rewarding and engaging people to do a great job and building up the shareholder value. Talented people and their rewarding is a key factor in SHV. Earnings can’t be measured yet as a performance because no quarterly business to measure. The third element is the future business the company strives for. We hope option plans strike a good balance with the potential future business. The risk is only shareholder’s risk and it is good to understand when and where all the key factors have and will or had given their insights and input. Good to understand when it is important to encourage and stimulate with options.

There will be the day when I enjoy Aura as a beer.

I had a bear https://en.m.wikipedia.org/wiki/Karhu_(beer)

All the encouraging news lately are a logical continuum of their science. The sky is open because no setbacks for Bex so far. No one can take the responsibility in promising ultimate success as a mono and combo in solids and blood in the market. Anyway I think the Faron CFO is spending restless nights because if the share would soar 100 fold meaning Mcap more than 10b and less than 15 b which is close to Merck’s Keytruda’s annual sales in 2021 (17b$), would mean all the options would pretty much eat and danger the share capital if no treasury shares….I’ll have an other bear or shouldn’t I have had even the first one.

Thats Great News!

That’s great! Waiting for the next RNS!

All their work and investments done are good “biomarkers “ on behalf of a rising SP in the future.

Dracula, I agree and something is missing and we all want to see it in SP.

I guess these three are what you need to have as end results. Maybe now confidence to trust on biomarkers. Clever-1 expression is of course the “root cause” that explains their science and where Bex needs to bind to change the M2 phenotype in to M1 and so activates the immune system against cancer. After all we don’t know if it is intratumoral clever-1 or soluble clever-1 that finally breaks the back of the camel? Bex binds in both anyway. More simple way to go forward towards FDA?

Within a year I think otherwise a big disappointment, right. Actually the SP has to rise earlier to support further financing and avoid dilution.

I think coming weeks are critical for how the current excitement will break up in good or bad. The data from the first Bexmab treatments will tell a lot how the near future will turn out. If nothing exciting news the dilute time continues. Good news will rise the SP and increase confidence and expectations for other programs too. It may happen that finally the company and the share starts getting wider publicity and gets seen in the radar and starts trading well. The tide will turn and we’ll enjoy premium in the SP until the ultimate breakthrough. Meaning here that their drugs get approved and will get in the market with their full potential or the company gets sold to BP.

So once again some expectations built up and no matter what happens the laboratory runs in the background until to the very end no matter what noise around. And always something new.

At least I highly respect their efforts in science and no doubt they’re serious with the business.

These are my thoughts and I am truly outsider.

They are investing in their science which builds up shareholder value. And some day finally the share price goes up latest when an EUA or FDA approval granted. Of course partnership deals may rise the SP even before. Commercial success and how they will meet TAMs defines the SP in a more sustainable way depending also on the life time of their own patents and how viable the combination drugs and partners will be. Not to forget what kind of a valuation would a BP offer give for the share.

So many various drivers for the SP in a foreseeable future?

Yes Sax, we stick in mud but have to say it’s not a catastrophe share like many us tech companies or many biotech ones. Almost a year ago I mentioned here BBIO BridgeBio Pharma Ltd. listed in naz. The Mcap was 10b$ and SP was above 60$ at that time. Now around 1b$ and SP 7$. I thought at that time that the US listing does a favor for the share like it was. And even with Moderna share many could be in trouble etc…

We are almost like a not listed company insensitive to immediate market sentiment. Not suffering from bad demand with our non existing products. All depends on if clinical trial will work and of course if additional financing available.

A lot of Faron’s projects are promising and when successful we will be rewarded.